Back to results
US 6,664,258 B1Granted
Spirocyclic dopamine receptor subtype ligands
AssigneePfizer Inc.
InventorsAnton F. J. Fliri, Todd W. Butler
Life of this patent
Estimating the term…
Abstract
This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.
Claims8
A compound of the formula
- wherein a is oxygen, CH2, C(CH3)2, NR10, sulfur, SO or SO2;
- b is oxygen, CH2, C═O, C═NR11, C═NOH, SO2, Sulfur, SO, C═NO(C1-C5)alkyl or CR7R8;
- each of R1 through R8 is selected, independently, from hydrogen, halo, trifluoromethyl, cyano and hydroxy, or R7 and R8 together can be C(═O)NH2 or C(═O)N(C1-C4)alkyl, with the proviso that neither R7 nor R8 can be halo when a is oxygen, NR11, sulfur, SO or SO2;
- and
- each of R10 and R11 is selected, independently, from hydrogen, benzyl and (C1-C6)alkyl;
- and the pharmaceutically acceptable salts of such compounds.
3 more elements
Dependencies are inferred from the claim text.